+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Drug"

Hepatic Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Hepatic Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 38 Pages
  • Global
From
Germ Cell Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Germ Cell Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 47 Pages
  • Global
From
Primitive Neuroectodermal Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Primitive Neuroectodermal Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 43 Pages
  • Global
From
Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 40 Pages
  • Global
From
Papillary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Papillary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 36 Pages
  • Global
From
Pituitary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Pituitary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 35 Pages
  • Global
From
Benign Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Benign Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 81 Pages
  • Global
From
Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 42 Pages
  • Global
From
Paraganglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Paraganglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 42 Pages
  • Global
From
Wilms Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Wilms Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 43 Pages
  • Global
From
Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 52 Pages
  • Global
From
Neuroendocrine Gastroenteropancreatic Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Neuroendocrine Gastroenteropancreatic Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 59 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 85 Pages
  • Global
From
Anti-Tumor Drugs Companies in China - Product Thumbnail Image

Anti-Tumor Drugs Companies in China

  • Report
  • November 2023
  • 65 Pages
  • China
From
Anti-Tumor Drugs Markets in China - Product Thumbnail Image

Anti-Tumor Drugs Markets in China

  • Report
  • November 2023
  • 214 Pages
  • China
From
Drug Delivery in Cancer - Technologies, Markets & Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets & Companies

  • Report
  • November 2021
  • 747 Pages
  • Global
From
Elemene Antitumor Drugs. Molecular Compatibility Theory and its Applications in New Drug Development and Clinical Practice - Product Thumbnail Image

Elemene Antitumor Drugs. Molecular Compatibility Theory and its Applications in New Drug Development and Clinical Practice

  • Book
  • April 2023
Diagnostic and Therapeutic Applications of Exosomes in Cancer - Product Thumbnail Image

Diagnostic and Therapeutic Applications of Exosomes in Cancer

  • Book
  • May 2018
Loading Indicator

The Tumor Drug market is a subset of the Oncology Drugs market, which focuses on the development and sale of drugs used to treat cancer. These drugs are used to target and destroy cancer cells, reduce the size of tumors, and reduce the spread of cancer. Tumor drugs are typically divided into two categories: cytotoxic drugs, which kill cancer cells, and targeted therapies, which target specific molecules involved in cancer growth. These drugs are often used in combination with other treatments, such as radiation and surgery, to maximize the effectiveness of treatment. The Tumor Drug market is highly competitive, with many companies developing and selling drugs to treat cancer. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. Other companies, such as AstraZeneca, Eli Lilly, and Amgen, are also active in the market. Show Less Read more